Gozde Kar

机构：AstraZeneca (United Kingdom) · ORCID：0009-0002-7473-2725

发表论文 63 篇 · 总被引 4105 次 · h-index 22

代表论文

• Ferroptosis of tumour neutrophils causes immune suppression in cancer (2022 · Nature · 被引 548)
• Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial (2023 · Cancer Discovery · 被引 126)
• Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer (2022 · Journal for ImmunoTherapy of Cancer · 被引 87)
• Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer (2021 · Journal of Clinical Investigation · 被引 76)
• The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment (2024 · Nature Communications · 被引 62)
• Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial (2025 · Nature Medicine · 被引 35)